AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01245205
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04648540
Drug: Dexmedetomidine 0.5 mic/kg/h
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours
Trial: NCT00792701
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00792701
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00553930
Drug: Pegylated interferon alfa-2a and Ribavirin
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
Trial: NCT00553930
Drug: Pegylated interferon alfa 2a and Ribavirin
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of \>= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
Trial: NCT02291679
Drug: Linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00032279
Drug: Visilizumab
RxNorm normalized name: Visilizumab
DrugBank: Visilizumab (DB12053)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01962285
Drug: propofol targel controlled infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
Trial: NCT00456833
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02048072
Drug: Gilenya
RxNorm normalized name: Gilenya
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Autonomic testing during first dose administration of Gilenya.
Trial: NCT03153579
Drug: LSD
RxNorm normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysergic Acid Diethylamide~200ug per os, single dose
Trial: NCT01509911
Drug: TL-118
RxNorm normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
Trial: NCT01509911
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Monthly cycles of 3 weekly treatments a month and one week off of treatment
Trial: NCT01068158
Drug: 0.5% Ivermectin Cream
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
Trial: NCT00698334
Drug: INH, Rifampicin, Ethambutol and Pyrazinamide
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
Trial: NCT00364741
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During and 2 hours after surgery
Trial: NCT03948191
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
Trial: NCT03948191
Drug: 99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
RxNorm normalized name: (99Tc)pertechnetate
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
Trial: NCT03620253
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Trial: NCT02276222
Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer
RxNorm normalized name: clozapine
DrugBank: SUN-101 (DB17238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
Trial: NCT03076099
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
Trial: NCT00377325
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/Kg/day; daily; liquid form; 6 months
Trial: NCT00568048
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
Trial: NCT01963325
Drug: S-1 plus Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
Trial: NCT03372122
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A cloth to cleanse and disinfect the skin
Trial: NCT02813070
Drug: [18F] Flutemetamol
DrugBank: Flutemetamol (18F) (DB09151)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PET brain imaging and Magnetic resonance brain imaging
Trial: NCT01379170
Drug: Euthyrox (levothyroxine)
RxNorm normalized name: levothyroxine Oral Tablet [Euthyrox]
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
Trial: NCT01012232
Drug: 20 mL ropivacaine 5 mg/mL
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01012232
Drug: 10 mL ropivacaine 10 mg/mL
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02617017
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
Trial: NCT03752216
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria.
Trial: NCT00983086
Drug: Flavanones of orange juice
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
Trial: NCT01951625
Drug: Vericiguat (BAY1021189) (1.25 mg)
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25 mg BAY1021189 tablets
Trial: NCT01951625
Drug: Vericiguat (BAY1021189) (5 mg)
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg BAY1021189 tablets
Trial: NCT00642187
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00817362
Drug: IPI-504
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IPI-504 IV infusion 300 mg/m2
Trial: NCT00817362
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
Trial: NCT00436293
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m²
Trial: NCT01592370
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered PO
Trial: NCT01592370
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered PO and by IV infusion
Trial: NCT00436293
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m²
Trial: NCT03285906
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy Apatinib：500 mg，po，qd
Trial: NCT03395756
Drug: Depot-Medroxyprogestereone Acetate
RxNorm normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 150 mg intramuscular depot medroxyprogesterone acetate
Trial: NCT01395641
Drug: gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
Trial: NCT00425113
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02598505
Drug: Indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00019227
Drug: pentetic acid calcium
RxNorm normalized name: Pentetic acid
DrugBank: Pentetic acid (DB14007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00830960
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral, daily, 90 days
Trial: NCT00830960
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, daily, 90 days
Trial: NCT02823080
Drug: Cetrorelix
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
Trial: NCT03351439
Drug: Zopiclone
RxNorm normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
Trial: NCT03351439
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
Trial: NCT03351439
Drug: Celebrex
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
Trial: NCT03351439
Drug: Percocet
RxNorm normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT03217448
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
Trial: NCT03217448
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
Trial: NCT00550485
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram 4 mg
Trial: NCT03351439
Drug: Naprosyn
RxNorm normalized name: Naprosyn
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT01530555
Drug: Rabbit ATG, Thymoglobuline (Genzyme)
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months
Trial: NCT04461028
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
Trial: NCT04461028
Drug: Bupivacaine with Dexamethasone Solution
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
Trial: NCT02706119
Drug: Subcutaneous glargine insulin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
Trial: NCT01170221
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Linezolid 600 mg twice daily for 10 days
Trial: NCT01047592
Drug: sarcosine
RxNorm normalized name: Sarcosine
DrugBank: Sarcosine (DB12519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarcosine, 2 g/d , oral, for 12 weeks
Trial: NCT01047592
Drug: sarcosine+ BE
DrugBank: Sarcosine (DB12519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
Trial: NCT00365391
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally, 150 mg, every day during each cycle.
Trial: NCT00054236
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fludarabine IV over 30 minutes on days -8 to -4
Trial: NCT00054236
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
Trial: NCT00559650
Drug: Cinaciguat (BAY58-2667)
RxNorm normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
Trial: NCT01795430
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01795430
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01795430
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01795430
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00086736
Drug: bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01795430
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00086736
Drug: eflornithine
RxNorm normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00086736
Drug: oral bicalutamide placebo
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00833560
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
Trial: NCT00833560
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
Trial: NCT00455975
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab
Trial: NCT00649168
Drug: BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Trial: NCT00961116
Drug: Fenofibric Acid (Fibricor™) 105 mg Tablet
RxNorm normalized name: fenofibric acid 105 MG [Fibricor]
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
Trial: NCT00961116
Drug: Fenofibrate (Tricor®) 145 mg Tablet
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
Trial: NCT00198458
Drug: Vitrase
RxNorm normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00219388
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04492475
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.